Series A Completed
Kanvas Biosciences Series A
US$48m raised
Announced 6 May 2026
Investors
Led by
- DCVC · Co-lead
With
- Gates Foundation
Investors as the sources name them; a linked name has a FundComb profile.
- Company
- Kanvas Biosciences
- Stage
- Series A
- Amount raised
- US$48m
- Company based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development
Similar rounds
- Vedana Therapeutics Series A Jun 2026 · US$46m · led by Canaan
- Nectar Social Series A May 2026 · US$30m · led by Menlo Ventures
- Amperos Health Series A Apr 2026 · US$16m · led by Bessemer Venture Partners
- Phonely Series A Apr 2026 · US$16m · led by Base10 Partners
- NODA AI Series A Feb 2026 · US$25m · led by Bessemer Venture Partners
Sources
- 6 May 2026 Kanvas makes the microbiome druggable—and the implications are massive dcvc.com